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Objectives To determine the safety, tolerability and
signs of efficacy of MOR103, a human monoclonal
antibody to granulocyte–macrophage colony-stimulating
factor (GM-CSF), in patients with rheumatoid arthritis
(RA).
Methods Patients with active, moderate RA were
enrolled in a randomised, multicentre, double-blind,
placebo-controlled, dose-escalation trial of intravenous
MOR103 (0.3, 1.0 or 1.5 mg/kg) once a week for
4 weeks, with follow-up to 16 weeks. The primary
outcome was safety.
Results Of the 96 randomised and treated
subjects, 85 completed the trial (n=27, 24, 22 and 23
for pooled placebo and MOR103 0.3, 1.0 and
1.5 mg/kg, respectively). Treatment emergent adverse
events (AEs) in the MOR103 groups were mild or
moderate in intensity and generally reported at
frequencies similar to those in the placebo group. The
most common AE was nasopharyngitis. In two cases,
AEs were classified as serious because of hospitalisation:
paronychia in a placebo subject and pleurisy in a
MOR103 0.3 mg/kg subject. Both patients recovered
fully. In exploratory efficacy analyses, subjects in the
MOR103 1.0 and 1.5 mg/kg groups showed significant
improvements in Disease Activity Score-28 scores and
joint counts and significantly higher European League
Against Rheumatism response rates than subjects
receiving placebo. MOR103 1.0 mg/kg was associated
with the largest reductions in disease activity
parameters.
Conclusions MOR103 was well tolerated and showed
preliminary evidence of efficacy in patients with active RA.
The data support further investigation of this monoclonal
antibody to GM-CSF in RA patients and potentially in
those with other immune-mediated inflammatory
diseases.
Trial registration number NCT01023256
INTRODUCTION
Despite major advances in the treatment of
rheumatoid arthritis (RA), many patients are unable
to achieve treatment goals.1 2 There is thus a con-
tinuing need for the exploration and development
of therapeutic strategies with novel mechanisms of
action.
One molecule that may play a critical role in
inflammatory arthritis is granulocyte–macrophage
colony-stimulating factor (GM-CSF). Although ori-
ginally characterised by its ability to promote
myeloid haematopoiesis, GM-CSF is associated
with a multitude of additional effects on mature
myeloid cells, including stimulation of the produc-
tion of inflammatory mediators by neutrophils and
macrophages3 4 and promotion of the differenti-
ation and pathogenicity of proinflammatory T-
helper 17 cells.5 6
Several lines of data suggest that GM-CSF
strongly influences the development and pathogen-
esis of RA.7 Animal models support a key role for
this molecule in both initiating and exacerbating
inflammatory arthritis.8–11 In humans, GM-CSF is
found at elevated levels in the synovial tissue and
fluid of patients with RA.12 13 Exacerbation of
established RA has been reported in patients who
received GM-CSF as supportive therapy.14 15 More
recently, clinical trials have found that GM-CSF
receptor-α blockade reduced disease activity in
patients with RA.16 17
Targeting the cytokine directly by means of a
monoclonal antibody to GM-CSF provides an
alternative means of blocking GM-CSF. MOR103
is a high-affinity recombinant human IgG1 anti-
body that binds to a GM-CSF epitope, thereby
blocking cytokine–receptor interaction and recep-
tor activation.18 Although GM-CSF receptor block-
ade and direct GM-CSF targeting are both
expected to block GM-CSF-mediated signalling,
the targeting of receptor versus cytokine could
potentially result in different target-mediated drug
disposition. In addition, since MOR103 targets the
soluble cytokine, no antibody- or complement-
dependent cytotoxicity is anticipated. We report
the results of the first in patient study with
MOR103 in patients with RA.
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METHODS
Trial design and treatment
This trial (NCT01023256) was a randomised, double-blind,
placebo-controlled, multidose, dose-escalation trial of three
MOR103 doses (0.3, 1.0 and 1.5 mg/kg). These doses were
chosen on the basis of a previous safety study in healthy human
subjects and pharmacokinetic modelling of trough levels
required for GM-CSF inhibition in synovial tissue. Additional
information on the study drug manufacturer and intravenous
administration can be found in the online supplementary text.
Subject eligibility was determined at the screening visit (up to
35 days before treatment initiation) and confirmed at baseline
before the first dose on day 1. Eligible subjects were enrolled
into three cohorts according to a randomisation schedule
through an interactive web response system. All investigators
and participants were blinded to the study randomisation
scheme.
Each subject received a total of four doses, one per week at
baseline and days 8 (week 1), 15 (week 2) and 22 (week 3).
Subjects made follow-up visits to the trial centre at weeks 4, 5,
6, 8, 10, 13 and 16. An independent Data Safety Monitoring
Board (DSMB) reviewed an interim safety report with data from
at least 20 subjects in each of the first two cohorts (0.3 and
1.0 mg/kg). DSMB approval was required before the study was
allowed to proceed to the next higher dose. A second safety
review was performed when all subjects in these cohorts had
completed their week 5 visit.
The trial was initiated on 19 January 2010 and the last visit
was on 14 June 2012. Subjects were treated in 26 centres in
Europe (see online supplementary table S1 for participating
countries). The trial protocol was approved by the institutional
review boards or independent ethics committees at the partici-
pating sites and was conducted in accordance with the
Declaration of Helsinki (revised edition, Seoul 2008) and the
International Conference on Harmonisation Guidelines for
Good Clinical Practice. Patients provided written informed
consent for the trial before undergoing screening procedures.
Authors had full access to data and certify the accuracy and
completeness of data analysis.
Subjects
Men or women 18 years of age or older with active RA accord-
ing to the revised 1987 criteria of the American College of
Rheumatology (ACR)19 and a body mass index between 19.0
and 35.0 kg/m2 (inclusive) were eligible for this trial. Subjects
were required to have: (1) at least three swollen and three
tender joints using the Disease Activity Score-28 joints (DAS28)
joint count, with at least one swollen joint in the wrist or hand
excluding the proximal interphalangeal joints; (2) C-reactive
protein (CRP) levels >5 mg/L if seronegative for rheumatoid
factor and anti-cyclic citrullinated peptide antibody, or >2 mg/L
if seropositive for either marker; (3) DAS28 ≤5.1; and (4) ACR
functional class of I, II or III.20 Patients with high disease activ-
ity (DAS28 >5.1) were excluded as the efficacy of MOR103
was unknown. Subjects had to be willing to use effective contra-
ception, be surgically sterile or at least 2 years postmenopausal.
Previous treatment with biological/immunosuppressive therapies
other than cell-depleting agents was allowed with an adequate
washout period. Stable concomitant treatment with non-
biological disease-modifying antirheumatic drugs or low doses
of oral corticosteroids was allowed. Exclusion criteria were pres-
ence or history of major chronic inflammatory autoimmune
disease, clinically significant abnormalities in haematology
parameters, liver enzymes or pulmonary function tests (PFTs),
and significant systemic illness or malignancy.
Safety and tolerability assessments
The primary end point was the evaluation of safety and toler-
ability. Data on adverse events (AEs; MedDRA V.13.0), vital
signs, serum chemistry, haematology and urinalysis were col-
lected at each visit. Additional evaluations included coagulation
parameters, whole blood flow cytometry, and ECG. Samples for
laboratory analyses were collected before dosing. Laboratory
analyses were performed at a central laboratory (Eurofins
Medinet BV, Breda, The Netherlands).
Because high levels of GM-CSF autoantibodies have been
associated with idiopathic pulmonary alveolar proteinosis,21 22
serum surfactant D levels were measured at all visits except the
screening visit, and PFTs, including forced expiratory volume in
the first second (FEV1), vital capacity, forced vital capacity and
diffusing capacity of the lung for carbon monoxide (DLCO),
were performed at screening and weeks 2, 4, 10 and 16.
Decreased DLCO was reported as an AE only if judged to be
potentially clinically relevant by the treating physician. An add-
itional evaluation of patients experiencing a ≥20% decrease in
DLCO compared with screening was also conducted.
Serum levels of proinflammatory cytokines, including tumour
necrosis factor (TNF), interleukin (IL)-1β, IL-6, IL-8, IL-10,
interferon (IFN)-γ and GM-CSF (free cytokine only, not
MOR103-bound GM-CSF), were measured at baseline, weeks
1–4 and week 16 by use of the Cytokine Multiplex Kit (Life
Technologies GmbH, Darmstadt, Germany) and a Luminex
reader. A validated direct ELISA was used to test patient serum
samples for MOR103 antibodies at screening and weeks 10, 13
and 16. Bound drug antibodies were detected using anti-IgG- or
anti-IgM-specific secondary antibodies.
Clinical assessments
The primary exploratory efficacy outcome was change from
baseline in DAS28 calculated using the erythrocyte sedimenta-
tion rate as the acute phase reactant.23 Other exploratory effi-
cacy assessments included the proportions of patients achieving
European League Against Rheumatism (EULAR) response24 and
ACR improvement criteria25 and changes in DAS28 and ACR
core measures, including tender joint count (TJC; 69 joints),
swollen joint count (SJC; 66 joints), patient’s self-assessment of
pain (measured on a 100 mm visual analogue scale) and the
Health Assessment Questionnaire-Disability Index (HAQ-DI).26
Fatigue was measured at baseline and weeks 4, 8 and 16 by the
Functional Assessment of Chronic Illness Therapy (FACIT)-
fatigue self-assessment scale, which has been validated in RA.27
MRI of the wrist and hand was performed at screening, week 4
and week 8. The side with a swollen wrist or the most swollen
joints within the 2nd to 5th metacarpophalangeal (if neither or
both wrists were swollen) was selected for imaging; the right
side was chosen if swollen joints were equivalent. Two inde-
pendent experts blinded to patient data and image chronology
scored the images in a single reading campaign using the
Outcome Measures in Rheumatology (OMERACT) RA MRI
Studies (RAMRIS) scoring system.28 29 Central medical imaging
services were provided by BioClinica (Newton, Pennsylvania,
USA) and its affiliates.
Statistical methods
Data were analysed by descriptive statistics using SAS for
Windows, Release V.9.3. The Cochran–Mantel–Haenszel test
and Fisher’s exact test were used to determine p values for
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EULAR and ACR response rates, respectively. p Values for other
efficacy measures were derived from pairwise comparisons
between each dosage group and the pooled placebo group based
on an analysis of covariance (ANCOVA) model including
fixed-effect terms for dose and the covariate CRP level at base-
line. p Values were calculated on outcome parameters from
weeks 4 through 16 but not at earlier visits, as the efficacy
outcome of greatest interest was response after completion of
treatment. Post hoc analyses of differences in baseline demo-
graphic characteristics among groups used the Kruskal–Wallis
test. p<0.05 indicated significance.
To minimise the risk of exposing a large number of subjects
without evidence of clinical benefit, sample size calculations
were based on the primary exploratory efficacy outcome,
change in DAS28. Assuming a statistical power of 80%, an α of
0.05 (two-sided test), a common SD of 1.0, and a discontinu-
ation rate of 15%, we estimated that 21 subjects were required
for each MOR103 treatment group and seven subjects for each
placebo group (pooled placebo group of 21) to demonstrate a
difference of 1.0 point in mean DAS28 change from baseline in
the active group compared with placebo. This treatment differ-
ence was based on the DAS28 difference between active and
placebo treatments of 1.3–1.6 observed over 12 weeks with ada-
limumab,30 adjusted for length of exposure.
RESULTS
Subjects
Of the 288 subjects who were screened, 98 were randomised,
96 received treatment at 26 trial centres in Europe, and 85
(86.7%) completed the study (figure 1; see online supplemen-
tary table S1 for distribution by country). Two randomised
patients did not receive treatment and were excluded from all
analyses. All patients who received treatment (N=96; full ana-
lysis set) were included in outcome assessments.
Baseline demographic and clinical characteristics were gener-
ally comparable among treatment groups, although post hoc
analyses revealed differences in mean CRP levels and TJC that
reached the level of significance (table 1).
Safety and tolerability
A total of 144 treatment-emergent AEs were reported in 54
(56.3%) subjects (42 subjects (60.9%) in the MOR103 groups
(see online supplementary table S2) and 12 (44.4%) in the
pooled placebo group). The most common treatment-emergent
AE by preferred term in the active and placebo groups was naso-
pharyngitis (table 2). The incidences of fatigue, cough and AEs
related to RA (worsening or flares) in the MOR103 group were
>4% higher than in the placebo group. In eight of the nine
MOR103 subjects who reported RA exacerbations, this AE
occurred after the last dose of MOR103 (10 days to
>12 weeks), suggesting that disease flares were related to with-
drawal of active treatment. No cases of infusion reaction were
reported, but temporal correlations suggest that one case of rash
(MOR103 0.3 mg/kg) and one of fatigue (MOR103 1.0 mg/kg)
may have been related to MOR103 infusion. Nasopharyngitis,
fatigue, RA exacerbations, rhinitis and oropharyngeal pain
occurred at higher incidences (>4% higher) in the MOR103
1.0 mg/kg group than in other active treatment groups or the
pooled placebo group. These differences should be interpreted
with caution as they are based on small subject numbers.
None of the AEs were considered to be probably or definitely
related to treatment. AEs possibly related to treatment were
reported in seven placebo (14 AEs) and 10 MOR103 subjects
(19 AEs; table 3). Only three AEs (fatigue, anaemia and
decreased DLCO) were considered possibly related to treatment
in more than one subject.
All AEs were judged to be of mild or moderate intensity except
for one severe AE of hospitalisation due to paronychia in the
placebo group. The patient recovered fully. There were two
serious treatment-emergent AEs during the study: the aforemen-
tioned case of paronychia (placebo group) and pleurisy of moder-
ate intensity (MOR103 0.3 mg/kg group), both of which resulted
in hospitalisation. In the MOR103 subject, pleurisy was detected
5 days after the last dose of the trial. The patient was treated with
antibiotics and recovered fully. One treatment-emergent AE in a
placebo patient, decreased DLCO, resulted in treatment discontinu-
ation. There were no deaths in the trial.
Additional evaluations of subjects with a ≥20% decrease in
DLCO or alterations in PFTs did not reveal any patterns of
Figure 1 Disposition of patients with rheumatoid arthritis randomised to receive placebo or MOR103 in the full analysis set.
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concern in MOR103-treated patients (see online supplementary
text). There were no clinically important changes in surfactant
D levels, vital signs, ECG, whole blood flow cytometry or urine,
haematology or serum chemistry parameters during treatment
and no clinically important differences between active treatment
and placebo in these measures.
None of the peripheral blood cytokines evaluated in this trial
showed notable or consistent changes related to MOR103 infu-
sions (data not shown). The levels of GM-CSF and certain other
cytokines, including IFNγ, TNF and IL-10, remained at or near
the lower limit of quantification throughout the trial.
Serum samples were tested for anti-MOR103 IgG and IgM
antibodies. Only sporadic positives were detected (see online
supplementary text), and there was no evidence that antibodies
to MOR103 affected serum MOR103 concentrations or clinical
outcomes.
Efficacy
In exploratory investigations, the two higher doses of MOR103
were associated with significant reductions in disease activity.
Compared with the pooled placebo group, significantly greater
changes from baseline in DAS28 scores (the primary efficacy
outcome according to study protocol) were observed in the
MOR103 1.0 mg/kg group from weeks 4 through 10 and in the
MOR103 1.5 mg/kg group from weeks 4 through 6 (figure 2;
see online supplementary figure S1 for mean DAS28 scores
during treatment). There were no significant differences in
DAS28 changes between placebo and MOR 103 0.3 mg/kg.
In the MOR103 1.0 and 1.5 mg/kg groups, improvements in
DAS28 scores were observed at the earliest post-treatment visit
(week 1). By week 16, mean DAS28 scores were at or above
baseline in all groups except MOR103 1.0 mg/kg, which contin-
ued to maintain DAS28 scores at levels well below baseline. As
with DAS28, the MOR103 1.0 mg/kg group showed the most
pronounced effects in additional efficacy outcomes (highest
response rates and largest reductions in disease activity para-
meters; table 4).
MRIs were evaluated for synovitis, bone oedema and erosions
at weeks 4 and 8 by the OMERACT RAMRIS scoring system.
No statistically significant differences between the pooled
placebo group and any of the MOR103 groups were observed
(data not shown). The largest difference between active treat-
ment and placebo was for the MOR103 1.0 mg/kg synovitis
score at week 4 (−0.84 vs placebo; p=0.35).
DISCUSSION
A growing body of literature has documented the potential role
of GM-CSF in the pathogenesis of RA. Here we present the first
in patient data on the effects of GM-CSF blockade by means of
a fully-human antibody to GM-CSF, MOR103, in patients with
RA. Although the primary objective of this trial was to deter-
mine the safety and tolerability of multiple doses of MOR103,












Age (years) 53.8 (12.7) 57.4 (8.3) 49.0 (12.7) 53.0 (9.9)
Body mass index
(kg/m2)
26.3 (3.5) 26.3 (3.6) 26.1 (4.6) 25.7 (4.7)
Female, n (%) 19 (70.4) 21 (87.5) 17 (77.3) 18 (78.3)
Caucasian, n (%) 27 (100) 24 (100) 22 (100) 23 (100)
DAS28-ESR 4.88 (0.41) 4.88 (0.54) 4.78 (0.66)* 4.87 (0.38)
CRP (mg/L)† 18.2 (20.0) 23.1 (20.8) 11.7 (12.6) 18.0 (30.1)
ESR (mm/h) 28.7 (14.8) 28.1 (12.2) 21.9 (12.0) 24.9 (14.4)
Swollen joints 6.3 (3.2) 5.5 (2.3) 7.3 (4.7) 6.7 (2.5)
Tender joints† 9.4 (7.0) 8.0 (4.7) 12.3 (7.6) 11.3 (5.8)
RF positive,‡ n/N (%) 25/26 (96.2) 21/24 (87.5) 19/21 (90.5) 19/23 (82.6)
Anti-CCP positive,§
n/N (%)
17/25 (68.0) 16/21 (76.2) 16/21 (76.2) 16/22 (72.7)
Prior medication,¶ n (%)
Systemic
corticosteroids
18 (66.7) 21 (87.5) 13 (59.1) 16 (69.6)
DMARD** 21 (77.8) 18 (75.0) 15 (68.2) 20 (87.0)
TNF inhibitor 2 (7.4) 1 (4.2) 0 (0.0) 0 (0.0)
Concomitant medication at baseline, n (%)
Systemic
corticosteroids
19 (70.4) 20 (83.3) 13 (59.1) 15 (65.2)
DMARD** 26 (96.3) 22 (91.7) 17 (77.3) 21 (91.3)
MTX 21 (77.8) 18 (75.0) 14 (63.6) 19 (82.6)
Data are presented as mean (SD) unless otherwise indicated. For RF and anti-CCP
positive, percentages were calculated on the number of patients with data, not on
the full cohort size.
*One patient had missing data.
†p<0.05 for differences in mean values between groups by Kruskal–Wallis test.
‡Defined as >13.9 IU/mL.
§Defined as >5 U/mL.
¶Medication in the 3 months prior to screening.
**Conventional (non-biological) DMARDs.
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS, Disease Activity Score;
DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate;
MTX, methotrexate; RF, rheumatoid factor; TNF, tumour necrosis factor.
Table 2 Incidence of treatment-emergent adverse events
















12 (44.4) 13 (54.2) 14 (63.6) 15 (65.2) 42 (60.9)
Nasopharyngitis 3 (11.1) 1 (4.2) 7 (31.8) 1 (4.3) 9 (13.0)
RA* 0 (0.0) 3 (12.5) 4 (18.2) 2 (8.7) 9 (13.0)
Fatigue 1 (3.7) 1 (4.2) 4 (18.2) 1 (4.3) 6 (8.7)
Hypertension 1 (3.7) 1 (4.2) 2 (9.1) 2 (8.7) 5 (7.2)
Headache 1 (3.7) 1 (4.2) 0 (0.0) 2 (8.7) 3 (4.3)
Cough 0 (0.0) 1 (4.2) 0 (0.0) 2 (9.7) 3 (4.3)
Anaemia 0 (0.0) 0 (0.0) 0 (0.0) 2 (8.7) 2 (2.9)
Decreased DLCO 2 (7.4) 2 (8.3) 0 (0.0) 0 (0.0) 2 (2.9)
Oropharyngeal pain 1 (3.7) 0 (0.0) 2 (9.1) 0 (0.0) 2 (2.9)
Rhinitis 0 (0.0) 0 (0.0) 2 (9.1) 0 (0.0) 2 (2.9)
Rhinorrhoea 0 (0.0) 0 (0.0) 0 (0.0) 2 (8.7) 2 (2.9)
Viral respiratory
tract infection
0 (0.0) 0 (0.0) 0 (0.0) 2 (8.7) 2 (2.9)
Peripheral oedema 2 (7.4) 0 (0.0) 1 (4.5) 0 (0.0) 1 (1.4)
Rash 3 (11.1) 1 (4.2) 0 (0.0) 0 (0.0) 1 (1.4)
Upper respiratory
tract infection
2 (7.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Urinary tract
infection
3 (11.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Values shown are number (%) of subjects with events.
*Worsening or exacerbation of existing RA (flares). Except for one patient in the
MOR103 0.3 mg/kg group (date of flare not reported), all events occurred from
10 days to >12 weeks following the last dose of active treatment.
AE, adverse event; DLCO, diffusing capacity of the lung for carbon monoxide;
RA, rheumatoid arthritis.
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exploratory analyses provided suggestive evidence for the effi-
cacy of this agent.
In this phase Ib/IIa clinical trial, MOR103 was well tolerated
and associated with a satisfactory safety profile in patients with
active moderate RA who received up to four doses at weekly
intervals. Although overall rates of treatment-emergent AEs
were higher in the MOR103 groups (60.0%) compared with
placebo (44.4%), most treatment-emergent AEs occurred at
similar incidences. Fatigue, cough and RA worsening/flares (pri-
marily occurring after the end of active treatment) were
reported more frequently by MOR103 subjects than placebo
subjects. All treatment-emergent AEs in the MOR103 groups
were of mild or moderate intensity. One serious AE, pleurisy of
moderate intensity, occurred in a MOR103 subject (0.3 mg/kg)
and resolved on antibiotic treatment.
Because of the association between GM-CSF autoantibodies
and idiopathic pulmonary alveolar proteinosis,21 22 surfactant D
levels and PFTs were closely monitored. Decreased DLCO was
observed in some subjects, but there were no obvious differences
between placebo and active treatment groups. Surfactant D
levels remained normal and there was no overall pattern of PFT
alterations in MOR103-treated subjects. Similar findings on the
lung safety of anti-GM-CSF receptor therapy were reported in
the phase II mavrilimumab trial.17 Cytokine release was not
observed in MOR103-treated subjects. Anti-MOR103 antibody
testing detected only sporadic positives, and there was no clear
association between assay results and clinical outcomes.
In exploratory efficacy analyses, MOR103 resulted in signifi-
cant improvements relative to placebo in several outcome mea-
sures. The most pronounced effects were observed with
MOR103 1.0 mg/kg. The effect of this dose on disease activity
was robust for all major efficacy variables and over time, and
did not appear to be driven by geographical imbalance, individ-
ual centres, concomitant medications, or outliers. Subjects
treated with MOR103 1.5 mg/kg also showed significant
improvements in certain efficacy parameters, but the changes
were not as pronounced or as sustained as for MOR103 1.0 mg/
kg. A rapid onset of action was observed at both of the higher
MOR103 doses. MOR103 0.3 mg/kg resulted in significant
improvements over placebo in SJC at week 4, but did not affect
other measures of disease activity.
It seems unlikely that the discrepancy in clinical activity
between the 1.0 and 1.5 mg/kg doses reflects a true difference
in clinical efficacy, as the difference in dose is relatively small
and we are not aware of other studies of cytokine inhibition
with a bell-shaped optimum response curve. As for other phase
I/II clinical trials, limitations of this study include its small
Figure 2 Mean change from baseline
in DAS28 scores. Statistical significance
was not evaluated before the week 4
visit as specified in the study protocol.
DAS28, Disease Activity Score-28
joints.
Table 3 Incidence of possibly treatment-related AEs by preferred


















7 (25.9) 3 (12.5) 3 (13.6) 4 (17.4) 10 (14.5)
Fatigue 0 (0.0) 1 (4.2) 1 (4.5) 1 (4.3) 3 (4.3)
Anaemia 0 (0.0) 0 (0.0) 0 (0.0) 2 (8.7) 2 (2.9)
Decreased DLCO 1 (3.7) 2 (8.3) 0 (0.0) 0 (0.0) 2 (2.9)
Nasopharyngitis 2 (7.4) 1 (4.2) 0 (0.0) 0 (0.0) 1 (1.4)
Rash 2 (7.4) 1 (4.2) 0 (0.0) 0 (0.0) 1 (1.4)
Decreased FEV1 0 (0.0) 1 (4.2) 0 (0.0) 0 (0.0) 1 (1.4)
Sinus tachycardia 0 (0.0) 1 (4.2) 0 (0.0) 0 (0.0) 1 (1.4)
RA flare 0 (0.0) 0 (0.0) 1 (4.5) 0 (0.0) 1 (1.4)
Nausea 0 (0.0) 0 (0.0) 1 (4.5) 0 (0.0) 1 (1.4)
Oedema 0 (0.0) 0 (0.0) 1 (4.5) 0 (0.0) 1 (1.4)
Hypertension 0 (0.0) 0 (0.0) 1 (4.5) 0 (0.0) 1 (1.4)
Dermatitis 0 (0.0) 0 (0.0) 1 (4.5) 0 (0.0) 1 (1.4)
Oral herpes 0 (0.0) 0 (0.0) 0 (0.0) 1 (4.3) 1 (1.4)
Rales 0 (0.0) 0 (0.0) 0 (0.0) 1 (4.3) 1 (1.4)
Presyncope 0 (0.0) 0 (0.0) 0 (0.0) 1 (4.3) 1 (1.4)
Subjects could have more than one AE. Values shown are number (%) of subjects
with events.
*14 AEs in placebo group; 7 in MOR103 0.3 mg/kg; 6 in MOR103 1.0 mg/kg; 6 in
MOR103 1.5 mg/kg. Additional AEs in the placebo group that did not occur in a
MOR103 subject and are not shown in the table were increased liver function tests
(n=2) and one case each of pharyngitis, upper respiratory tract infection, urinary tract
infection, flank pain, oropharyngeal pain, exertional dyspnoea and haematoma.
AE, adverse event; DLCO, diffusing capacity of the lung for carbon monoxide;
FEV1, forced expiratory volume in the first second; RA, rheumatoid arthritis.
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sample size, limited duration, and exclusion of patients with
severe RA. Larger clinical trials are needed to define the optimal
MOR103 dosage.
It is too early to comment on possible differences in clinical
profiles between MOR103 and mavrilimumab, an antibody to
GM-CSF receptor.16 17 Because of the different targets of these
two agents (soluble cytokine vs membrane-bound receptor),
there may be differences in tolerability and spectrum of activity.
Further studies will be required to explore these issues.
The data presented here establish proof of concept for the
use of antibodies to GM-CSF in the treatment of RA and
support the initiation of larger clinical trials to confirm the
safety and efficacy of MOR103. Our findings suggest that
MOR103 has the potential to become a novel and valuable
therapeutic option for RA.
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Table 4 Efficacy outcomes at weeks 4 and 8
Outcome
Pooled placebo (N=27) MOR103
0.3 mg/kg (N=24) 1.0 mg/kg (N=22) 1.5 mg/kg (N=23)
Week 4 Week 8 Week 4 Week 8 Week 4 Week 8 Week 4 Week 8
Response assessments, n (%)
EULAR
Good 1 (3.7) 1 (3.7) 3 (12.5) 1 (4.2) 5 (22.7) 7 (31.8) 1 (4.3) 2 (8.7)
Moderate 1 (3.7) 6 (22.2) 6 (25.0) 7 (29.2) 10 (45.5) 6 (27.3) 15 (65.2) 11 (47.8)
None 20 (74.1) 15 (55.6) 14 (58.3) 13 (54.2) 6 (27.3) 6 (27.3) 7 (30.4) 10 (43.5)
Missing 5 (18.5) 5 (18.5) 1 (4.2) 3 (12.5) 1 (4.5) 3 (13.6) 0 (0.0) 0 (0.0)
p Value* – – 0.06 0.91 0.0002 0.019 0.0001 0.2565
ACR
ACR20 2 (7.4) 5 (18.5) 6 (25.0) 3 (12.5) 15 (68.2)† 7 (31.8) 7 (30.4) 6 (26.1)
ACR50 1 (3.7) 2 (7.4) 1 (4.2) 0 (0.0) 5 (22.7) 4 (18.2) 2 (8.7) 0 (0.0)
ACR70 0 (0.0) 0 (0.0) 1 (4.2) 0 (0.0) 1 (4.5) 2 (9.1) 0 (0.0) 0 (0.0)
Missing 5 (18.5) 5 (18.5) 1 (4.2) 3 (12.5) 1 (4.5) 2 (9.1) 0 (0.0) 0 (0.0)
Additional efficacy assessments, change from baseline in mean values (SD)
DAS28 0.2 (0.8) −0.1 (0.9) −0.2 (1.1) −0.3 (0.9) −1.1 (0.9)† −1.0 (1.3)‡ −0.6 (0.7)‡ −0.6 (0.9)
Swollen joints 0.1 (3.5) −0.8 (3.6) −1.7 (2.4)‡ −1.9 (2.2) −3.5 (5.1)‡ −4.1 (4.4)‡ −3.3 (3.2)‡ −3.3 (3.1)‡
Tender joints 2.0 (6.4) 2.1 (8.0) 0.1 (7.1) 0.3 (5.0) −4.8 (3.2)§ −6.8 (4.1)† −3.7 (6.2)‡ −4.0 (5.3)§
ESR (mm/h) 2.8 (12.5) 0.9 (13.1) 8.8 (24.5) 2.0 (16.6) −6.3 (12.5) −0.7 (17.4) −2.5 (17.7) −0.6 (14.3)
Pain −3.3 (16.5) −8.0 (16.1) −8.6 (22.8) −4.1 (23.1) −17.4 (17.2)‡ −13.4 (20.9) −11.4 (11.5) −9.5 (11.9)
HAQ-DI −0.45 (0.54) −0.44 (0.54) −0.21 (0.41)‡ −0.21 (0.56) −0.53 (0.52) −0.51 (0.56) −0.31 (0.24) −0.25 (0.22)
Physician GA −3.0 (15.7) −3.5 (16.3) −0.6 (19.7) −4.7 (20.0) −18.0 (19.6)‡ −18.1 (22.6)‡ −7.8 (10.8) −6.5 (13.4)
Patient GA −3.0 (16.1) −8.2 (17.5) −2.7 (20.5) −4.5 (21.9) −16.6 (15.6)‡ −13.3 (24.7) −6.0 (17.7) −4.0 (18.3)
FACIT fatigue scores 3.0 (8.1) 4.3 (9.1) 2.7 (9.2) 2.1 (5.6) 9.1 (10.2)‡ 9.4 (12.6) 3.1 (6.0) 4.7 (7.1)
*p Values for pairwise comparisons with pooled placebo group determined by Cochran–Mantel–Haenszel test (missing values not included).
†p<0.0001 for pairwise comparisons with pooled placebo group. Fisher’s exact test was used for ACR response (missing values not included) and ANCOVA was used for additional
efficacy assessments.
‡p<0.05 for pairwise comparisons with placebo group by ANCOVA.
§p<0.001 for pairwise comparisons with placebo group by ANCOVA.
ACR, American College of Rheumatology; ANCOVA, analysis of covariance; DAS28, Disease Activity Score-28 joints; ESR, erythrocyte sedimentation rate; EULAR, European League
Against Rheumatism; FACIT, Functional Assessment of Chronic Illness Therapy; GA, global assessment of disease activity; HAQ-DI, Health Assessment Questionnaire-Disability Index.
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